You are viewing: UAE Oral Proteins & Peptides Market analysis

The UAE Oral Proteins & Peptides Market was valued at $4.28 Million in 2025 and projected to reach to $7.98 Million by 2030, representing a compound annual growth rate of 13.3%. The UAE oral proteins & peptides market is poised for sustained expansion driven by increasing healthcare expenditure, growing patient awareness of advanced therapeutics, and government initiatives supporting pharmaceutical innovation.

UAE Oral Proteins & Peptides Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UAE Oral Proteins & Peptides Market Trends and Insights

  • The UAE's advanced healthcare infrastructure and rising prevalence of chronic diseases are driving demand for innovative oral protein and peptide therapeutics.
  • The UAE's strategic position as a regional healthcare hub and increasing investment in pharmaceutical R&D are accelerating market adoption. In the UAE, the oral proteins & peptides sector benefits from strong regulatory support and a growing patient population seeking non-invasive treatment options.
  • The UAE's healthcare sector's emphasis on precision medicine and biopharmaceutical innovation is positioning the market for sustained expansion through 2030.
  • The UAE's high healthcare spending and focus on preventive care create favorable conditions for oral protein and peptide product launches and market penetration..

Key Market Statistics

  • CAGR (2025-2030) 13.3% CAGR
  • Market Size, 2025 ~USD 4.28 Million
  • Forecast, 2030 ~USD 7.98 Million
  • Country UAE

UAE Oral Proteins & Peptides Market Overview

Market Valuation Growth :

The UAE oral proteins & peptides market is valued at USD 4.28 million in 2025, with a projected CAGR of 13.3%, reaching USD 7.98 million by 2030, reflecting strong regional demand.

Healthcare Infrastructure Advantage :

UAE's world-class healthcare infrastructure and regulatory framework position it as a regional hub for advanced therapeutics, attracting pharmaceutical investments and clinical research initiatives.

Chronic Disease Prevalence :

Rising incidence of diabetes, cardiovascular diseases, and metabolic disorders in the UAE population is driving demand for innovative oral protein and peptide-based therapeutic solutions.

Regional Hub Status :

UAE's strategic geographic location and economic stability make it a gateway for oral protein & peptide product launches across the Middle East and North Africa region.

UAE Oral Proteins & Peptides Market Dynamics

  • The market benefits from UAE's robust healthcare ecosystem, including state-of-the-art medical facilities and a highly educated population with strong purchasing power.
  • Pharmaceutical companies are increasingly establishing regional headquarters and R&D centers in the UAE, accelerating product development and market penetration.
  • The convergence of rising chronic disease prevalence, supportive regulatory policies, and strategic healthcare investments positions the UAE as a critical growth market for oral protein and peptide therapeutics in the coming years..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • The UAE oral proteins & peptides market is valued at USD 4.28 million in 2025 and is expected to reach USD 7.98 million by 2030, representing a 13.3% CAGR.
    • The UAE's advanced healthcare infrastructure and regulatory environment support rapid adoption of innovative oral protein and peptide therapeutics.
    • Growing prevalence of diabetes, obesity, and gastrointestinal disorders in the UAE is driving demand for oral protein and peptide-based treatments.
    • The UAE's position as a regional healthcare leader and investment in biopharmaceutical innovation create significant opportunities for market expansion through 2030.

    Oral Proteins & Peptides Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment OBESITY & OVERWEIGHT (Therapeutic Area)
    Forecast Period 2025–2030
    Growth Rate CAGR of 22.1% from 2025 to 2030
    Largest Segment TABLETS (Formulation)
    Market Size Base Year (Billions) ~USD 8.84 (2025)
    Revenue Forecast (Billions) ~USD 24 (2030)
    Segments Covered Molecule, Drug Class, Formulation, Therapeutic Area, End User

    UAE Oral Proteins & Peptides Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Molecule

    • Calcitonin
    • Linaclotide
    • Other Molecules
    • Plecanatide
    • Semaglutide
    • Trofinetide
    • Voclosporin

    By Drug Class

    • Cgrp Receptor Antagonists
    • Cnis
    • Gc-C Agonists
    • Glp-1 Receptor Agonists
    • Gpe
    • Other Drug Classes

    By Formulation

    • Capsules
    • Oral Solutions
    • Tablets

    By Therapeutic Area

    • Cns Disorders
    • Diabetes
    • Gastroenterology
    • Genetic Disorders
    • Nephrology
    • Obesity & Overweight
    • Other Therapeutic Areas

    By End User

    • Home Care Settings
    • Hospitals & Specialty Clinics
    • Long-Term Care Facilities

    UAE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HOME CARE SETTINGS1.612.73.013.363.864.635.25.8414.2
    HOSPITALS & SPECIALTY CLINICS0.470.770.850.931.061.251.391.5412.7
    LONG-TERM CARE FACILITIES0.661.11.221.361.551.852.072.3113.6
    TOTAL2.744.575.085.656.477.748.659.713.8

    Target Audience

    • Pharmaceutical Companies : Manufacturers and developers of oral protein and peptide therapeutics need UAE market data to identify growth opportunities, plan product launches, and establish regional distribution networks.
    • Healthcare Investors : Private equity firms and venture capital investors require detailed market analysis to evaluate investment opportunities in UAE's pharmaceutical and biotech sectors with strong growth potential.
    • Medical Device & Pharma Distributors : Regional distributors and healthcare suppliers need market insights to optimize inventory, negotiate partnerships, and expand their oral protein & peptide product portfolios in UAE.
    • Healthcare Providers & Hospitals : Hospital networks and healthcare institutions require market intelligence to understand treatment trends, procurement strategies, and patient demand for oral protein and peptide therapies.
    • Market Research & Consulting Firms : Research organizations and consultants need comprehensive UAE market data to support client advisory services, competitive analysis, and strategic planning in the pharmaceutical sector.

    Key Companies in the UAE Oral Proteins & Peptides Market

    CompanyHQOwnershipStrongest segments
    NOVO NORDISK A/SDenmarkPublic CompanyObesity and Diabetes Care – GLP-1 injectables (including Wegovy),Obesity and Diabetes Care – oral GLP-1 and other diabetes therapies,Rare Disease – rare blood and endocrine disorders,
    ABBVIE INC.United StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related autoimmune/inflammatory),Oncology/Hematology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev and related),
    PFIZER INC.IndiaPublic CompanyInternal medicine (CV, respiratory, gastro, multivitamins, neuroscience, women’s health),Vaccines,Injectables and anti-infectives,
    BAUSCH HEALTH COMPANIES INC.CanadaPublic CompanyBausch + Lomb (eye health),Salix (gastroenterology and hepatology),Solta Medical (aesthetic medical devices),
    ACADIA PHARMACEUTICALS INC.United StatesPublic CompanyNUPLAZID (Parkinson’s disease psychosis),DAYBUE / trofinetide (Rett syndrome),Pipeline and other revenues,
    AURINIA PHARMACEUTICALS INC.CanadaPublic CompanyLUPKYNIS (voclosporin) for lupus nephritis,Other pipeline and collaboration revenue (including aritinercept-related),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Hospital & Specialty (Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre),
    SWK HOLDINGSUnited StatesPrivate Investment FirmHealthcare venture debt (biopharma, medtech, diagnostics, life science tools),Healthcare services and HIT lending,Technology and SaaS venture debt (non-healthcare),
    ENTERA BIO LTD.IsraelPublic CompanyEB613 – oral teriparatide (osteoporosis, stress fractures),EB612 – hypoparathyroidism peptide replacement,EB618 – GLP-1/glucagon dual agonist (obesity, metabolic, fibrotic),
    ASTRAZENECA PLCUnited KingdomPublic CompanyOncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Imjudo, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, diabetes combinations),Respiratory & Immunology (Symbicort, Fasenra, Tezspire, Breztri, Airsupra, others),

    NOVO NORDISK A/S

    Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 with 67,900 employees. Operating as a public company, it is a major player in the global pharmaceutical industry.

    ABBVIE INC.

    AbbVie Inc. is a United States-based public pharmaceutical company established in 2012 with 57,000 employees. The company operates in the pharmaceutical sector with significant global operations.

    PFIZER INC.

    Pfizer Inc. operates as a public company in India with 1,244 employees, having been established in 1950. The company is engaged in pharmaceutical operations in the Indian market.

    BAUSCH HEALTH COMPANIES INC.

    Bausch Health Companies Inc. is a Canadian public company with 20,300 employees operating in the pharmaceutical and healthcare sectors.

    ACADIA PHARMACEUTICALS INC.

    Acadia Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1993 with 797 employees. The company focuses on pharmaceutical development and commercialization.

    AURINIA PHARMACEUTICALS INC.

    Aurinia Pharmaceuticals Inc. is a Canadian public company established in 1993 with 128 employees. The company operates in the pharmaceutical sector.

    MERCK & CO., INC.

    Merck & Co., Inc. is a United States-based public pharmaceutical company founded in 1891 with 74,000 employees. It is one of the world's largest pharmaceutical manufacturers.

    SWK HOLDINGS

    SWK Holdings is a United States-based private investment firm founded in 1996 with 9 employees.

    ENTERA BIO LTD.

    Entera Bio Ltd. is an Israeli public company founded in 2009 with 21 employees operating in the pharmaceutical sector.

    ASTRAZENECA PLC

    AstraZeneca PLC is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It is a major global pharmaceutical manufacturer.

    Reasons to Buy this Report

    • Market Entry Strategy : Gain comprehensive insights into UAE's oral proteins & peptides market dynamics to develop targeted market entry strategies and identify high-potential segments for product launches.
    • Competitive Intelligence : Understand competitive landscape, key players, and market positioning specific to UAE to benchmark your offerings and identify differentiation opportunities in this growing market.
    • Investment Decision Support : Access detailed market forecasts and growth drivers to support investment decisions, partnership evaluations, and resource allocation for UAE pharmaceutical operations.
    • Regulatory & Market Insights : Obtain UAE-specific regulatory requirements, reimbursement frameworks, and healthcare policies essential for successful product commercialization and market compliance.
    • Regional Expansion Planning : Leverage UAE market data as a foundation for broader Middle East expansion strategies, utilizing the country's position as a regional healthcare and pharmaceutical hub.

    Frequently asked questions

    What is the current size of the UAE oral proteins & peptides market?

    The UAE oral proteins & peptides market is valued at USD 4.28 million in 2025 and is projected to grow to USD 7.98 million by 2030.

    What is the expected growth rate for the UAE oral proteins & peptides market?

    The UAE oral proteins & peptides market is expected to grow at a compound annual growth rate (CAGR) of 13.3% from 2025 to 2030.

    What factors are driving growth in the UAE oral proteins & peptides market?

    Key drivers include the UAE's advanced healthcare infrastructure, rising prevalence of chronic diseases, strong regulatory support, and increasing investment in biopharmaceutical innovation.

    Which therapeutic areas are most prominent in the UAE oral proteins & peptides market?

    The UAE market is seeing significant demand in diabetes management, obesity treatment, and gastrointestinal disorder therapies, driven by increasing disease prevalence.

    How does the UAE market compare to other GCC countries?

    The UAE's market size of USD 4.28 million (2025) reflects its position as a leading healthcare hub in the GCC region with advanced infrastructure and regulatory frameworks.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva; research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Oral Proteins and Peptides Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The bottom-up approach was used to estimate and validate the total size of the oral proteins and peptides market. These methods were also extensively utilized to estimate the size of various subsegments within the market. The research methodology used to estimate the market size includes the following:

    • The list of approved oral proteins and peptides was identified through extensive secondary and primary research.
    • The oral protein and peptide products in the pipeline were identified from clinical trial registries and from secondary and primary research related to peptide and protein therapeutics.
    • The revenues generated from these oral proteins and peptides were determined through annual reports and secondary sources (including paid databases).
    • The products were categorized according to market segments. Percentage shares and splits were calculated based on revenue contributions for each segment. This information was validated using secondary sources and insights from industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Oral Proteins and Peptides Market Size: Bottom-up Approach

    Oral Proteins and Peptides Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Oral proteins and peptides are therapeutic drugs made from proteins or peptides (short chains of amino acids) that are meant to be taken by mouth. These biologically active molecules are designed to treat a variety of medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty clinics
    • Long-term care facilities
    • Patient advocacy organizations
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
    • To benchmark players within the oral proteins and peptides market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

     

    Get the Full Oral Proteins & Peptides Market Report

    Full forecast, segment splits, and company analysis for all Oral Proteins & Peptides Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status